{"id":69045,"date":"2026-06-29T21:59:55","date_gmt":"2026-06-29T13:59:55","guid":{"rendered":"https:\/\/flcube.com\/?p=69045"},"modified":"2026-06-29T21:59:56","modified_gmt":"2026-06-29T13:59:56","slug":"abbvies-skyrizi-wins-fda-approval-for-pediatric-psoriasis-expanding-il-23-blocker-to-children-six-and-older","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69045","title":{"rendered":"AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older"},"content":{"rendered":"\n

AbbVie (NYSE: ABBV<\/a>)<\/strong> announced on June 26, 2026, that the U.S. Food and Drug Administration (FDA)<\/strong> has approved SKYRIZI (risankizumab)<\/strong> for the treatment of children six years of age and older<\/strong> with moderate-to-severe plaque psoriasis<\/strong> who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis. This marks a significant expansion of the IL-23 inhibitor into the pediatric population.<\/p>\n\n\n\n

Regulatory Expansion Timeline<\/h2>\n\n\n\n
Indication<\/th>FDA Approval<\/th>EMA Approval<\/th>Patient Population<\/th><\/tr><\/thead>
Plaque Psoriasis (Adult)<\/strong><\/td>Approved<\/td>Approved<\/td>Adults with moderate-to-severe disease<\/td><\/tr>
Psoriatic Arthritis<\/strong><\/td>Approved<\/td>Approved<\/td>Adult patients<\/td><\/tr>
Crohn’s Disease<\/strong><\/td>Approved<\/td>Approved<\/td>Adult patients<\/td><\/tr>
Ulcerative Colitis<\/strong><\/td>Approved<\/td>Approved<\/td>Adult patients<\/td><\/tr>
Pediatric Plaque Psoriasis<\/strong><\/td>Jun 2026<\/strong><\/td>Pending<\/td>Children \u22656 years<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Mechanism & Scientific Profile<\/h2>\n\n\n\n